Liraglutide changes body composition and lowers added sugar intake in overweight persons with insulin pump-treated type 1 diabetes

Signe Schmidt , Christian S. Frandsen, Thomas F. Dejgaard, Dorte Vistisen, Thorhallur Halldorsson, Sjúrður Fróði Olsen, Jens-Erik B. Jensen, S. Madsbad, Henrik Andersen, Kirsten Nørgaard

Research output: Contribution to journalArticlepeer-review

Abstract

Aims: To present secondary outcome analyses of liraglutide treatment in overweight adults with insulin pump-treated type 1 diabetes (T1D), focusing on changes in body composition and dimensions, and to evaluate changes in food intake to identify potential dietary drivers of liraglutide-associated weight loss.Materials and methodsA 26-week randomized placebo-controlled study was conducted to investigate the efficacy and safety of liraglutide 1.8 mg daily in 44 overweight adults with insulin pump-treated T1D and glucose levels above target, and demonstrated significant glycated haemoglobin (HbA1c)- and body weight-reducing effects. For secondary outcome analysis, dual X-ray absorptiometry scans were completed at Weeks 0 and 26, and questionnaire-based food frequency recordings were obtained at Weeks 0, 13 and 26 to characterize liraglutide-induced changes in body composition and food intake.ResultsTotal fat and lean body mass decreased in liraglutide-treated participants (fat mass -4.6 kg [95% confidence interval {CI} -5.7; -3.5], P ConclusionsLiraglutide lowered fat and lean body mass compared with placebo. Further, liraglutide reduced intake of added sugars. However, no significant difference in total daily energy intake was detected between liraglutide- and placebo-treated participants.
Original languageEnglish
Pages (from-to)212-220
Number of pages9
JournalDiabetes, obesity and metabolism
Volume24
Issue number2
DOIs
Publication statusPublished - 30 Sep 2021

Keywords

  • body composition
  • food frequency
  • insulin pump therapy
  • liraglutide
  • type 1 diabetes
  • weight loss

Fingerprint

Dive into the research topics of 'Liraglutide changes body composition and lowers added sugar intake in overweight persons with insulin pump-treated type 1 diabetes'. Together they form a unique fingerprint.

Cite this